

HETEROCYCLES, Vol. 92, No. 3, 2016, pp. 397 - 421. © 2016 The Japan Institute of Heterocyclic Chemistry  
Received, 13th November, 2015, Accepted, 15th January, 2016, Published online, 28th January, 2016  
DOI: 10.3987/REV-15-830

## TOTAL BIOSYNTHESIS OF FUNGAL INDOLE DITERPENES USING CELL FACTORIES

Atsushi Minami, Chengwei Liu, and Hideaki Oikawa\*

Division of Chemistry, Graduate School of Science, Hokkaido University,  
Sapporo 060-0810, Japan, hoik@sci.hokudai.ac.jp

**Abstract** – Reconstitution of biosynthetic genes in a heterologous host is a newly emerging method for synthesis of fungal secondary metabolites. Application of this method to indole diterpenes is described. We have successfully elucidated all of the individual enzymatic steps and produced four representative indole diterpenes, paspaline, paxilline, aflatrem, and penitrem, at a yield of ~100 mg/L. These results confirmed that the *Aspergillus oryzae* expression system is highly reliable for elucidation of biosynthetic pathways, even those involving 17 enzymatic reactions.


### CONTENTS

1. Introduction
2. Expression system of biosynthetic genes in *Aspergillus oryzae*
3. Indole diterpenes produced by various fungi
4. Enzymatic synthesis of fungal indole diterpenes
  - 4-1. Paspaline
  - 4-2. Paxilline
  - 4-3. Aflatrem
  - 4-4. Penitrem
5. Conclusion

### 1. INTRODUCTION

In 1917, Robinson reported outstanding total synthesis of tropinone.<sup>1</sup> He carefully chose three simple starting materials to set up the sequential reactions (condensation to form iminium ion, Mannich reactions, and decarboxylations), as shown in Scheme 1. Intriguingly, he envisioned the occurrence of the reactions in a cell under physiological conditions, and used starting materials that are likely present in plant cells.

This method of synthesis incorporates a biogenetic viewpoint that greatly simplifies the route for synthesis of tropinone. Living organisms synthesize numerous natural products, such as tropinone, from simple metabolites using biosynthetic enzymes. Recent progress in the biosynthesis of natural products provides a basic understanding of the biosynthetic pathways of representative natural products such as polyketides, terpenoids, and alkaloids including nonribosomal and ribosomal peptides at the enzymatic level. In microorganisms, biosynthetic genes are usually found in clusters on the chromosome. Recent rapid progress in DNA sequencing technology has produced large publically available databases of genomic data. Web-based search tools have enabled identification of the gene clusters for biosynthesis of many natural products. Thus, using this information, we can basically synthesize any type of natural products if we can find a method to express gene clusters. In addition, the Web tools also reveal a vast number of natural product gene clusters, most of which have yet to be characterized. Contrary to previous predictions, this finding suggests that discovery of novel natural products may be possible by expression of these dormant gene clusters.



Scheme 1. Biomimetic synthesis of tropinone by Robinson

Natural products have been isolated using bioassay-guided screening in many cases. Conventional chemical synthesis is an alternative method for supplying natural products. In addition, as described, reconstitution of biosynthetic gene clusters in heterologous hosts has become an attractive method to produce natural products. Since 2010, we have investigated the enzymatic synthesis of fungal natural products by using gene cluster data in the *Aspergillus oryzae* expression system. We and others have successfully applied this system to produce various types of natural products.<sup>2-8</sup> In this review, we introduce recent efforts for the enzymatic total biosynthesis of indole diterpenes.

## 2. EXPRESSION SYSTEM OF BIOSYNTHETIC GENES IN *ASPERGILLUS ORYZAE*

From more than a thousand years, the fungus *A. oryzae* has been used in Japan to produce fermented

products, such as sake and soy sauce, at the industrial scale. Following development of genetic engineering methods, strains of *A. oryzae* that can secrete large amounts of proteins have been used for industrial enzyme production.<sup>9,10</sup> Among the various fungal expression systems available, such as the standard host *A. nidulans*, one of the most effective system is expression under the starch-inducible  $\alpha$ -amylase promoter in strains of *A. oryzae* lacking the ability to produce most secondary metabolites.

The high level of protein expression in this fungus is dependent on a powerful inducible promoter, such as *P<sub>amyB</sub>*, which is regulated by malto-oligosaccharides (Figure 1).<sup>11</sup> The plasmid pTAex3 consists of the *amyB* expression cassette (the *P<sub>amyB</sub>* promoter and the *T<sub>amyB</sub>* terminator) and an *argB* selectable marker.<sup>12</sup> Because this promoter is so robust, heterologous gene expression in *A. oryzae* has been used for the functional analysis of individual biosynthetic genes such as the multifunctional gene polyketide synthase which is involved in the production of fungal secondary metabolites. During the transformation process, biosynthetic genes are randomly integrated into the chromosome, thus requiring screening for transformants that show a good production (~100 mg/kg, yields are often higher in solid medium than in liquid medium).

Transformed cells harboring a target gene are usually selected using markers of antibiotic resistance, such as hygromycin or zeocin. However, *A. oryzae* is naturally resistant to various antibiotics, probably due to the presence of a high number of transporter genes. Therefore, several auxotrophic mutants of *A. oryzae* are used as hosts together with vectors having selectable markers complemented by *argB* (for an arginine auxotroph), *pyrG* gene (for a uridine auxotroph), *sC* gene (for a methionine auxotroph), *adeA* gene (for an adenine auxotroph) and *niaD* gene (for a nitrate assimilation mutant) (Figure 1). A few antibiotic resistant markers, including pPTR1 (pyrithiamine), are also used for introducing target genes.




Figure 1. *Aspergillus oryzae* expression system

Since 2010, in our group, the use of the *A. oryzae* expression system has been extended for reconstitution

of the biosynthetic machinery for fungal secondary metabolites (Figure 2). Multiple vectors are required to introduce all of the biosynthetic genes in the clusters. To examine the expression of multiple natural product biosynthetic genes, we selected an expression system using the quadruple-auxotrophic host *Aspergillus oryzae* NSAR1 (*niaD*<sup>-</sup>, *sC*<sup>-</sup>,  $\Delta$ *argB*, *adeA*<sup>-</sup>) developed by Kitamoto et al.<sup>13</sup> This host strain can accept multiple vectors such as pTAex3,<sup>12</sup> pUNA,<sup>14</sup> pUSA<sup>15</sup> and pAdeA<sup>16</sup> in addition to pPTRI<sup>17</sup> with the pyrithiamine-resistant marker (Figure 1).




Figure 2. Outline of reconstitution approach of biosynthetic genes for production of fungal natural products

Use of multiple vectors enabled us to produce simple natural products. However, production of more complex natural product requires a large number of genes. In addition, transformation and screening of the metabolite producing-transformant are time-consuming steps (2-4 weeks/gene). For the rapid reconstitution of the biosynthetic machinery in *A. oryzae*, we used the vectors pUARA2 and pUSA2 carrying tandemly arranged promoter/terminator set,<sup>18</sup> which were provided by Prof. Gomi. They constructed those vectors based on the previously developed pTAex3 and pUSA vectors containing the *argB* and *sC*-selectable markers, respectively. The vectors utilize the *P<sub>amyB</sub>* promoter, so that all of the target genes introduced at the cloning site can be overexpressed in *A. oryzae*. Tandem transformation utilizing two plasmids (genes: *A*, *C*; plasmids: *pA*, *pC*) with the same selectable marker is efficient, requiring use of fewer vectors and allowing a rapid introduction of biosynthetic genes to obtain transformants (*AO-A/C*, *AO-A*, *AO-C*) (Figure 3). Analysis of these transformants provides sufficient data for the identification of individual gene functions (Figure 3). In the biosynthetic study of natural product, a rapid process is preferable for screening of the genes essential for the conversion of interest.




Figure 3. Tandem transformation for rapid preparation of transformants containing multiple genes

### 3. INDOLE DITERPENES PRODUCED BY VARIOUS FUNGI

Indole-diterpenes (IDTs) were initially isolated from various ascomycetes fungi as potent tremorgenic mammalian mycotoxins. They also show additional unique biological activities such as inhibition of calcium-activated potassium channels,<sup>19</sup> tremorgenic activity,<sup>20</sup> potent and selective progesterone receptor agonistic activity,<sup>21</sup> and anti-MRSA activity.<sup>22</sup> Their wide range of biological activities are associated with their structural diversity. IDTs have various types of core structures which consist of indole and C<sub>20</sub>-polyprenyl moieties, and further modifications, such as prenylation and oxygenation (hydroxylation, epoxidation, and oxidative cyclization) yield more than one hundred family members.<sup>23,24</sup> Representative IDTs include the simple emindole, nominine, and paspaline (**1**), and the more elaborated members paxilline (**2**), aflatrems (**3**), lolitrems, nodulisporic acid and penitrems (**4**) (Figure 4). Intriguingly, many of the fungi that form symbiotic relationships with plants produce these toxins, suggesting that the toxin-producing ability of the fungi may contribute to establish these ecological associations.




Figure 4. Representative indole diterpenes produced by various fungi


## 4. ENZYMATIC SYNTHESIS OF FUNGAL INDOLE DITERPENES

### 4-1. Paspaline

Nearly 70% of IDTs have a characteristic hexacyclic skeleton that is presumably derived from paspaline (**1**) (Figure 4). Therefore, elucidation of a detailed reaction pathway for the core scaffold is important for versatile enzymatic synthesis of IDTs. Previous feeding experiments using tryptophan or anthranilic acid<sup>25,26</sup> suggested that either tryptophan or its precursors, such as indole-3-glycerol phosphate (IGP: **5**), could be used as a substrate for the synthesis of a common intermediate, 3-geranylgeranyl indole (GGI: **6**) (Schemes 2 and 3). A series of feeding experiments with <sup>13</sup>C-labeled acetate revealed that the terpenoid core structure is derived from geranylgeranyl diphosphate (GGPP: **7**).<sup>25,27</sup> The structure of the less-modified indole diterpenes, paspaline suggested that **1** is a cyclization product of **6**. This was experimentally supported by incorporation of deuterium labeled **6** into **1**.<sup>28</sup>


In 2001, the first biosynthetic gene cluster for biosynthesis of an IDT, paxilline (*pax*) was identified from *Penicillium paxilli*.<sup>29</sup> Gene inactivation and gene transfer to paxilline negative deletion mutants confirmed that four *pax* genes, *paxG* (GGPP synthase), *paxC* (prenyltransferase), *paxM* (FAD dependent monooxygenase), and *paxB* (hypothetical membrane protein), are required for the biosynthesis of **1**.<sup>29,30</sup> Recently, two more biosynthetic gene clusters for aflatrem (*atm*) and lolitrem (*ltm*) have been identified; four homologous genes (*atmGCMB* and *ltmGCMB*) were identified, adding to our understanding of the biosynthesis of indole diterpenes.<sup>31,32</sup> Although *paxB* shows homology to a functionally characterized *pyr4*, a membrane binding protein catalyzing epoxide-opening initiated cyclization in meroterpenoid pyripyropene biosynthesis,<sup>33</sup> little is known about the detailed function of the products of these four genes.

To confirm the roles of the four essential genes, we prepared four plasmids, pAdeA-*paxG*, pTAex3-*paxC*, pUSA-*paxM*, and pAdeA-*paxB*. Using the plasmids pAdeA-*paxG* and pTAex3-*paxC*, we transformed *A. oryzae* NSAR1 to obtain the transformant AO-*paxGC*, which produced **6** (7.7 mg/L). To this transformant, we further introduced *paxM*, yielding AO-*paxGCM*, which produced epoxy-GGI (**8**) (32 mg/L). Further incorporation of *paxB* into the transformant yielded AO-*paxGCMB*, which produces **1** (57 mg/L). The successful in vivo synthesis of **1** allowed us to determine the outline of the paspaline biosynthesis catalyzed by the four gene products (Scheme 2).<sup>34</sup> Interestingly, unlike total synthesis of natural products, the yield of each product was increased as the number of incorporated genes increased. However, following the elucidation of the biosynthetic pathway, two questions remained: 1) determination of the actual substrates of the PaxC reaction; 2) the cyclization mechanism catalyzed by PaxM and PaxB.



Scheme 2. Stepwise introduction of paspaline biosynthetic genes into *A. oryzae*


To determine the substrate of the initial geranylgeranylation step in the GGI forming reaction, in collaboration with Prof. Dairi, we performed an *in vitro* analysis using recombinant PaxC, which has a characteristic diphosphate-binding motif, to yield reactive allylic carbocation for alkylation of the indole ring at the C3 position. As expected from the previous reports, **5** undergoes geranylgeranylation by PaxC to afford **6**. Surprisingly, the reaction also proceeds using an indole as the substrate, although kinetic analysis showed that **5** is the preferred substrate for PaxC ( $k_{\text{cat}}/K_{\text{M}}$  for **5**;  $28.2 \text{ mM}^{-1}\text{s}^{-1}$ , indole;  $3.6 \text{ mM}^{-1}\text{s}^{-1}$ ). Further analysis of the reaction product revealed that PaxC catalyzes geranylgeranylation of **5**, accompanied by elimination of glyceraldehyde 3-phosphate as a byproduct. This dearomatization-elimination process is novel in the reaction of prenyltransferases (Scheme 3). To the best of our knowledge, the only previously known example is an octaprenyltransferase, MenA, which catalyzes simultaneous prenylation and decarboxylation in menaquinone biosynthesis in *Escherichia coli*.<sup>35</sup>




Scheme 3. Proposed mechanism of the prenyltransferase, PaxG, and the functionally related enzyme MenA

We then turned our attention to the mechanism of the subsequent epoxidation and cyclization. Isolation of **8** and **1** from the *AO-paxGCM* and the *AO-paxGCMB* suggested that PaxM catalyzes regioselective epoxidation to give **8**, and the subsequent cyclization of **8** yields the emindole SB (**9**).<sup>36</sup> However, the reaction did not terminate at this stage and a second round of epoxidation/cyclization of **9** afforded **1** (Scheme 4). To validate this stepwise epoxidation/cyclization mechanism, we performed a biotransformation study using **8** and the bisepoxide **10**, synthesized by the sequential Sharpless asymmetric dihydroxylations, as substrates. Incubation of **8** with a *paxB*-containing transformant, *AO-paxB*, of which was confirmed by semi-quantitative RT-PCR,<sup>29</sup> led to the formation of **9**. Importantly, *AO-paxB* also converted **10** into **1**. These results showed a previously unknown mechanism involving two rounds of stepwise epoxidation-cyclization via **9** (Scheme 4). In the biosynthesis of the polyether antibiotic, lasalocid, the epoxidase Lsd18 catalyzes sequential epoxidations and the cyclase Lsd19 catalyzes cascade cyclization of the bisepoxide (Scheme 5).<sup>37</sup> Although PaxM and PaxB catalyze similar epoxidation-cyclizations, the reaction sequence is quite different from those found in the biosynthesis of polyether antibiotic.






Scheme 4. Proposed stepwise mechanism for construction of the paspaline core using the epoxidase PaxM and the cyclase PaxB



Scheme 5. Proposed mechanism for construction of the polyether antibiotic lasalocid with the epoxidase Lsd18 and the cyclase Lsd19

Among the various known epoxide opening-initiated polyene cyclizations, catalysis of squalene 2,3-epoxide by oxidosqualene cyclase (OSC) to a complex tetracyclic ring system is one of the most well-known.<sup>38</sup> Although the amino acid sequences of OSC and PaxB are quite different, both enzymes catalyze similar sequential cyclizations. In 2003, Matsuda and co-workers reported biomimetic synthesis of petromindole from a regioisomer of epoxyGGI with a triterpene cyclase of plant origin (Scheme 6).<sup>39</sup> This enzymatic synthesis provided further support for the similarity between the reactions catalyzed by PaxB and steroid/triterpene cyclases. Biomimetic synthesis of protected epoxyGGI analogs with Lewis acids produced a multicyclic product similar to IDT in moderate yields.<sup>40</sup> However, no product containing a paspaline-like ring system was produced.



Scheme 6. Preparation of the indole diterpene, petromindole with triterpene synthase


#### 4-2. Paxilline

In the paxilline (**2**) gene cluster described in Section 4-1, two genes encoding cytochrome P450 monooxygenases, *paxP* and *paxQ*, were identified. Their functions were examined by gene disruption studies of *paxP* and *paxQ*, which led to accumulation of paspaline (**1**) and 13-desoxypaxilline (**11**), respectively (Scheme 7). A feeding experiment using **1** and  $\beta$ -PC-M6 (**12**), conducted in a transformant harboring *paxP* showed their conversion to **11**. These data indicated that PaxP and PaxQ catalyze multiple oxidation steps of **1** to **2** via **12** and **11**.<sup>41</sup>

To achieve synthesis of **2** in *A. oryzae*, we added two more genes *paxPQ* to the AO-*paxGCMB*. Due to limitations of the available vectors, we used tandem transformation to introduce two genes with a single vector, pUNA. In this transformation, two types of transformants, one containing *paxP* and the other containing *paxPQ*, were obtained. The former, AO-*paxGCMBP*, produced **11** and the latter, AO-*GCMBPQ*, produced **2** (35 mg/L) (Scheme 7). **11**, an oxidative product of **1**, is constructed by oxidative elimination of a methyl group as formic acid, via 1) stepwise oxidation of a methyl group to aldehyde, and 2) abstraction of a neighboring hydrogen atom to eliminate HCO<sub>2</sub>H. Subsequent allylic oxidation of **11** gives **2**.

In the cholesterol biosynthesis, an angular C14-methyl group is oxidatively eliminated to give olefin and formic acid.<sup>42</sup> After hydroxylation and dehydrogenation catalyzed by cytochrome P450, the resultant formyl group is oxidatively eliminated to give olefin and formic acid (Scheme 7). In the reaction catalyzed by PaxP, a similar multistep oxidation proceeds to give olefin but the reaction is not terminated at this point. Subsequently, PaxP hydroxylates at C10 to give  $\beta$ -alcohol **12**, that is further oxidized to the

ketone **11**. PaxQ hydroxylates **11** at the C13 position to afford **2**. Similar multiple oxidations occur during the biosynthesis of isotrichotriol<sup>43,44</sup> and gibberellins,<sup>45</sup> suggesting that they are a common synthetic strategy in fungal metabolite biosynthesis.




Scheme 7. Proposed mechanism of the cytochrome P450s PaxP and PaxQ, and a similar transformation in the steroid biosynthesis

### 4-3. Aflatrem

The potent mammalian tremorgens aflatremes (**3**), which are produced by *A. flavus* are structurally related to **2**.<sup>46</sup> The core skeleton of **3** is presumably derived by modifications of **2** (C20/C21 prenylation and C7 oxidation) as shown in Scheme 8. The structural similarity suggested that the aflatrem gene cluster would contain a gene set for construction of a paxilline skeleton. A conventional genomic DNA library search using a specific DNA probe and a bioinformatics-guided search of genome sequences has revealed aflatrem clusters (*atm*), which consists of the paspaline core construction genes (*atmGCMB*) and the oxidative modification genes (*atmPQ*) and an aflatrem-specific prenylation gene (*atmD*). Involvement of this cluster in aflatrem biosynthesis was supported by *atmPQ* gene complementation experiments of utilizing a *paxPQ* deletion mutant of a paxilline-producing strain, thus revealing the involvement of cytochrome P450s (AtmPQ) in the oxidative transformation of **1** to give paspalinine (**13**).<sup>31</sup> Recently, the function of the prenyltransferase AtmD was studied by in vitro analysis utilizing **2** instead of **13**.<sup>47</sup>

To develop a versatile method for synthesis of IDTs via **1**, we examined the reconstitution of **1** in *A. oryzae* applying a tandem transformation method, which is a rapid and an efficient gene incorporation

method to save the number of vectors and to shorten a length of time for reconstitution and functional analyses. The first tandem transformation of *A. oryzae* NSAR1 was carried out with pUARA2-*paxGC* and pUARA2-*paxMB*. One of the more than twenty transformants obtained from a single transformation produced **1** (54 mg/kg). A second tandem transformation of this transformant with pUSA2-*atmPQ* and pUSA-*atmD* gave three transformants producing **13** (88 mg/kg) and another three transformants producing aflatrem (**3a**) and  $\beta$ -aflatrem (**3b**) (54 mg/kg, 18 mg/kg). This is the first report of the total biosynthesis of **3** (Scheme 8). Remarkably, the introduction of the 7 genes required for aflatrem biosynthesis was achieved in only two rounds of transformations.<sup>18</sup>




Scheme 8. Tandem transformation of *atm* biosynthetic genes into *A. oryzae*

PaxQ homologs usually catalyze only C13-hydroxylation whereas AtmQ catalyzes oxidative cyclization at C7 and C13-hydroxylation to yield **13**, although we could not isolate a putative intermediate, paspalicine.<sup>48</sup> The reaction commenced with oxidation at the C7 allylic position and the resultant hemiacetal gave a cyclic acetal with a hydroxyl group at C27 to give paspalicine. Subsequent oxidation at the C13 allylic position of paspalicine yielded **13** (Scheme 9).

Dimethylallyl transferase (DMAT) is a well-known modification enzyme that is used in the biosynthesis of various natural products. Prenylation commonly occurs alcohol and amino groups. In addition, C-prenylation of the aromatic substrates such as indole moiety of IDTs is also known in the late stage of biosynthesis.<sup>49,50</sup> To date, the known DMATs involving IDT biosynthesis catalyze highly regioselective

C-prenylation at C2, and C4-C7 positions of indole. The prenylation modes ( $\alpha$  vs  $\gamma$ ) are strictly controlled by individual DMATs. In the aflatrem biosynthesis, AtmD showed  $\gamma$ -selective prenylation although the regioisomers **3a** and **3b** were obtained in a 3:1 ratio (Scheme 9).




Scheme 9. Proposed late stage biosynthetic pathway of aflatrem

Very recently, Tang and co-workers reported combinatorial synthesis of IDTs in *A. flavus*. This fungus contains a stand-alone cyclase, *AfB* (an *atmB* homolog).<sup>51</sup> Co-expression of *AfB* with *atmGCM* affords the alternative IDTs nominine and aflavinine, along with aflatrem. This observation indicates that after duplication of IDT cluster, *A. flavus* chose combinatorial synthesis (keeping a single copy of the gene encoding cyclization enzyme) over independent synthesis of IDTs using two individual clusters.

#### 4-3. Penitrem

To apply the simple and rapid reconstitution method to the elucidation of the synthesis of the most highly elaborated natural products, we chose the indole diterpene, penitrem (4), which has a unique tricyclic system adjacent to the paxilline core structure (Figure 4). Biosynthetic studies with isotopically labeled precursors including paxilline, suggested that the characteristic penitrem core scaffold is derived from a diprenylated paxilline derivative.<sup>25,52</sup>

At the beginning, structural analysis of penitrem congeners A~F isolated from *P. crustosum*<sup>53,54</sup> suggested that the late 3-step conversions of penitrem D (**4d**) to A (**4a**) consists of epoxidation (**4d** to B (**4b**)), benzylic hydroxylation (**4b** to E (**4e**)) and promiscuous chlorination (**4d** to C (**4c**); **4b** to F (**4f**); **4e** to **4a**). In addition, based on isolation of potential intermediates, paspaline (**1**),<sup>55</sup> PC-M4 (**14**), and PC-M5 (**15**),<sup>56,57</sup> we hypothesized that its biosynthetic pathway was divided into 3 stages (Scheme 10); stage I: from IGP (**5**) and GGPP (**7**) to paxilline (**2**) or its equivalent via **1**; stage II: **2** to **14** via **15**; stage III: **14** to **4a**. At this point, we can not eliminate the possibility that they are dead end products from biosynthetic intermediates.




Scheme 10. Metabolites from penitrem-producing fungi, and hypothesis for penitrem biosynthesis

We then performed a genomic analysis of the penitrem-producing fungus *P. simplicissimum*. Using gene cluster search tools (a local BLAST search and the 2ndFind program<sup>58</sup>), we identified a gene cluster that contained genes homologous to those of the paxilline gene cluster. However, this cluster lacked several genes for oxidative modifications of the indole ring. Therefore, we performed an RNA-seq analysis of another penitrem producer, *P. crustosum*. This analysis identified a second gene cluster, and the expression profile of these genes was closely correlated to that of the genes in cluster I. Eventually, we identified a penitrem gene cluster (*ptm*) consisting of genes encoding 17 biosynthetic enzymes (6 genes

homologous to the paxilline biosynthetic genes, *ptmGCMBPQ*; 2 prenyltransferase genes, *ptmDE*; 6 genes encoding oxidative transformation enzymes, *ptmJKLNOU*; and 3 genes for modification enzymes, *ptmHIV*.

Initially, we examined the Stage I transformation. As in the case of aflatrem, we introduced the *ptmPQ* genes to the transformant AO-*paxGCMB*, which produces **1**. This transformant produced **2** (8.8 mg/kg) but not  $\beta$ -PC-M6 (**12**), suggesting that PtmP catalyzes a 5-step transformation, similar to PaxP, and that the functionally unknown enzyme reduces **2** to a  $\beta$ -alcohol (Scheme 11).




Scheme 11. Proposed penitrem biosynthetic pathway of Stages I and II

During Stage II, two prenylations, a C10 reduction and a dehydration, are expected to occur. To determine the biosynthetic reaction sequence, we prepared the transformant AO-*ptmHD* by introducing the *ptmHD* genes, which encode a NAD(P<sup>+</sup>)-dependent oxidoreductase and a prenyltransferase, into *A. oryzae* NSAR1. The resultant transformant converted **2** to  $\beta$ -paxitriol (**16**) and a C20-prenylated analog (**17**) of **16** (Schemes 11, 12). Considering the remaining transformations in the Stage II, 3 genes (*ptmE*, prenyltransferase; *ptmV*, acetyltransferase; *ptmI*, unknown) are likely involved in the reaction. Three transformants, AO-*ptmHDV*, AO-*ptmHDVI* and AO-*ptmHDVIE*, were prepared from AO-*ptmHD*. While incubation of AO-*ptmHDV* with **2** did not give a predominant product, that of AO-*ptmHDVI* gave the 20-prenylpenijanthine (**19**) (Scheme 11). Although no acetylation product was obtained, this formal dehydration process likely involves acetylation and elimination of acetic acid. Similar formal dehydration processes (acetylation and elimination) have been reported in the biosynthesis of tetronate antibiotics.<sup>59,60</sup>

To obtain additional information on the reaction sequence involved in Stage II, we employed an in vitro


functional analysis of the prenyltransferase PtmD. Enzymatic reactions with three substrates, **2**, **16** and penijanthe (**18**), synthesized from paxilline with the recombinant PtmD in the presence of dimethylallyl diphosphate (DMAPP) showed a clear substrate preference, in the following order: **16**, **18**, and **2** (Scheme 12). This result suggested that the three-step conversion proceeded from C10-ketoreduction (PtmH), to C20-prenylation (PtmD), to dehydration (PtmV, PtmI). In the microbial conversion of **2** with AO-*ptmHDVIE*, no product other than **19** was obtained, indicating that, prior to PtmE catalyzed prenylation, an oxidation is involved in the later step of Stage II (most likely after the second prenylation). Thus, we turned our attention to functional analysis of the genes encoding oxidation enzymes, to reduce the number of possible reaction pathways (Scheme 12).




Scheme 12. Proposed penitrem biosynthetic pathway (Stage II)

To address the critical issue of whether PC-M4 (**14**) is a shunt metabolite or an actual intermediate, we prepared transformants AO-*ptmKLJ*, AO-*ptmKUN*, AO-*ptmKULNJ* and AO-*ptmKULNO*. Microbial conversion of **14** with AO-*ptmKLJ* or AO-*ptmKUN* gave a new product secopenitrem D (**20**) and **4c**, respectively. In addition, AO-*ptmKULNJ* and AO-*ptmKULNO* afforded **4a** and **4f**, respectively. These results showed that **14** is an intermediate of penitrem biosynthesis, and also that the five genes *ptmKULNJ* are essential for the Stage III transformations, and that PtmJ catalyzes the last benzylic hydroxylation (Scheme 13). To elucidate the detailed biosynthetic pathway of the Stage III transformations, we prepared the transformants AO-*ptmL*, AO-*ptmK*, AO-*ptmN* and AO-*ptmJ*. The conversion of **14** with these transformants established that the reaction proceeds via a 5-step sequential oxidative transformation (Scheme 14); the first half involves ring expansion-cyclic ether formation and the latter half involves epoxidation-hydroxylation-chlorination.






Scheme 13. Functional analyses of genes for Stage III of penitrem biosynthesis




Scheme 14. Proposed penitrem biosynthetic pathway (Stage III)

To elucidate the skeletal construction of **14**, we introduced two additional genes, *ptmOE*, into *AO-ptmHDVI*. Incubation of **2** with the resultant *AO-ptmHDVIOE* yielded **14**. The *in vitro* transformation of **19** with the recombinant flavin-dependent monooxygenase PtmO yielded a single acid-labile product, PC-M5 (**15**). Incubation of **15** with the recombinant PtmE in the presence of  $\text{Mg}^{2+}$  and DMAPP gave **14**. PtmE did not accept any other precursors. These data established that the Stage II biosynthetic pathway proceeds from **2** to **14** via the key intermediates **19** and **15** (Scheme 15).



Scheme 15. Prenylation-initiated cationic cyclization catalyzed by PtmE

In overall enzymatic transformations, the construction mechanism of bicyclo[4,2,0]octane system is especially intriguing. Prenylation-initiated cationic cyclizations are rather rare transformation in natural product biosynthesis (Schemes 15, 16). Head-to-head couplings of DMAPP and the subsequent cyclization give chrysanthemyl diphosphate (cyclopropane)<sup>61</sup> and cyclolavandulyl diphosphate (cyclohexene).<sup>62</sup> A bicyclo[3,3,1]nonane system of the antidepressant agent hyperforin was proposed to be constructed by prenylation of the geranyl group at the phloroglucinol moiety, followed by the nucleophilic attack of the internal enol.<sup>63,64</sup> The oxidative ring expansion catalyzed by a cytochrome P450 monooxygenase PtmK is another highlight of the penitrem biosynthesis (Scheme 16), although a similar ring expansion catalyzed by a non-heme Fe/ $\alpha$ -ketoglutarate dependent dioxygenase has been reported in the biosynthesis of cephalosporin.<sup>65</sup> Subsequent formation of the 8-membered oxocane cyclic ether is catalyzed by the cytochrome P450 monooxygenase PtmU (Scheme 16). In organic synthesis, this type of medium-sized ring formation is rather difficult to achieve owing to non-bonding transannular repulsion. A previous example of oxidative cyclic ether formation catalyzed by a cytochrome P450 has been reported in the biosynthesis of aureothin.<sup>66</sup>



Scheme 16. Characteristic construction mechanism of penitrem left-half core

## 5. CONCLUSION

It has long been believed that biosynthesis of natural products is a black box, and that the reactions could not be reproduced in laboratories. However, recent remarkable progress in DNA sequencing and bioinformatic technologies has enabled us to obtain blueprints (in the form of a list of biosynthetic genes) for natural products. With this information, elucidation of all of the individual enzymatic reaction steps, using an appropriate expression system, provides sufficient knowledge of how complex molecules are synthesized in nature. Once we can elucidate the detailed biosynthetic mechanism of a representative member of a specific family of natural products, we can propose a versatile plan for synthesis of family members, as in organic synthesis.

In this review, we describe our approach for synthesis of fungal indole diterpenes. Using the robust *A. oryzae* expression system, we developed a general strategy for constructing the core scaffold using 3 reaction steps (introducing an oligoprenyl group to the indole; regiospecific epoxidation; and programmed cyclization). Based on this finding, we developed a rapid method for construction of a transformant harboring the key genes *paxGCMB*, which could produce the versatile precursor paspaline. Using this transformant, we synthesized a simple paxilline (2 genes), aflatrems (3 genes), and a highly elaborated decacyclic penitrem (2 + 6 + 5 genes). This powerful approach enables us not only to synthesize a target natural product but also to access intermediates which are not readily synthesized. Thus, we are able to study intriguing reaction mechanisms, such as the construction of the bicyclo[4.2.0]octane core scaffold via the bicyclo[3.2.0]heptane system, in the biosynthesis of penitrem. Through this project, we showed that the *A. oryzae* heterologous expression system is highly reliable for

studying fungal natural product biosynthesis.

Because biosynthetic approaches typically use enzymes whose catalytic efficiencies have already been optimized, we used the catalyst without further modification. Without optimizing the expression level, we were able to produce the target molecule at a level of ~100 mg/L solely by screening for higher-yielding strains. In 2014, Sanofi produced artemisinic acid at 25 g/L using engineered yeast cells harboring a sesquiterpene synthase, a monooxygenase, and genes for 3 other enzymes.<sup>67</sup> The intermediate acid is further converted to the anti-malarial agent artemisinin via a chemical process at a scale of 60 t/year. This example shows that industrial optimization can provide various improvements, such as increased substrate supply, shutout of branched pathways, and fermentation conditions sufficient for industrial production. Therefore, simple lab-scale production is a promising first step to be scaled up to an industrial level.

From a synthetic point of view, enzymatic regio- and stereoselective oxidations are unique for manipulation of highly functionalized intermediates without protecting groups. For example, more than half of the 17 enzymes in penitrem biosynthesis catalyze oxidative transformations such as hydroxylation, epoxidation, halogenation, oxidative elimination, oxidative ring expansion, and cyclic ether formation. In addition, recent studies have shown that multistep oxidative transformation with a single enzyme is frequently involved in the biosynthesis of natural products, as in the case of PaxP (5 reaction steps). Similar observations have been reported in the biosynthesis of the fungal metabolites T-2 toxin,<sup>43,44</sup> austinol,<sup>68</sup> terretonin,<sup>8</sup> and fumagillin,<sup>69</sup> representative enzymes for which include  $\alpha$ -ketoglutarate-dependent dioxygenases, monooxygenases of cytochrome P450, and flavin-dependent enzymes. Modification of a small number of enzyme groups is sufficient to diversify natural products, suggesting that rational engineering of these oxidation enzymes can be applied for oxidations of both basic and applied chemical process.

Currently, a number of oxidation enzymes have been characterized. Thus, in the near future we can expect to construct a huge library of useful enzymes. Considering that stereostructures can be experimentally determined or obtained by precise simulation, we may be able to create the desired catalysts by rational design and engineering of enzymes and altering their substrate specificity.

## ACKNOWLEDGEMENTS

Authors sincerely thank to all co-workers and collaborators appeared in the original papers. This work was supported by the MEXT research grant on innovative area 22108002 to H. Oikawa.

## REFERENCES

1. R. Robinson, *J. Chem. Soc., Trans.*, 1917, **111**, 762.
2. T. Ugai, A. Minami, R. Fujii, M. Tanaka, H. Oguri, K. Gomi, and H. Oikawa, *Chem. Commun.*, 2015, **51**, 1878.
3. R. Fujii, T. Ugai, H. Ichinose, M. Hatakeyama, T. Kosaki, K. Gomi, I. Fujii, A. Minami, and H. Oikawa, *Biosci. Biotechnol. Biochem.*, in press, DOI: 10.1080/09168451.2015.1104234.
4. R. Fujii, A. Minami, T. Tsukagoshi, N. Sato, T. Sahara, S. Ohgiya, K. Gomi, and H. Oikawa, *Biosci. Biotechnol. Biochem.*, 2011, **75**, 1813.
5. R. Chiba, A. Minami, K. Gomi, and H. Oikawa, *Org. Lett.*, 2013, **15**, 594.
6. Y. Ye, A. Minami, A. Mandi, C. Liu, T. Taniguchi, T. Kuzuyama, K. Monde, K. Gomi, and H. Oikawa, *J. Am. Chem. Soc.*, 2015, **137**, 11846.
7. Y. Matsuda, T. Wakimoto, T. Mori, T. Awakawa, and I. Abe, *J. Am. Chem. Soc.*, 2014, **136**, 15326.
8. Y. Matsuda, T. Iwabuchi, T. Wakimoto, T. Awakawa, and I. Abe, *J. Am. Chem. Soc.*, 2015, **137**, 3393.
9. P. Barbesgaard, H. P. Heldt-Hansen, and B. Diderichsen, *Appl. Microbiol. Biotechnol.*, 1992, **36**, 569.
10. D. Lubertozzi and J. D. Keasling, *Biotechnol. Adv.*, 2009, **27**, 53.
11. S. Tada, Y. Iimura, K. Gomi, K. Takahashi, S. Hara, and K. Yoshizawa, *Agric. Biol. Chem.*, 1989, **53**, 593.
12. (a) T. Fujii, H. Yamaoka, K. Gomi, K. Kitamoto, and C. Kumagai, *Biosci. Biotechnol. Biochem.*, 1995, **59**, 1869; (b) K.-X. Huang, I. Fujii, T. Ebizuka, K. Gomi, and U. Sankawa, *J. Biol. Chem.*, 1995, **270**, 21495.
13. F. J. Jin, J. Maruyama, P. R. Juvvadi, M. Arioka, and K. Kitamoto, *FEMS Microbiol. Lett.*, 2004, **239**, 79.
14. O. Yamada, B. R. Lee, K. Gomi, and Y. Iimura, *J. Biosci. Bioeng.*, 1999, **87**, 424.
15. O. Yamada, S. N. Nan, T. Akao, M. Tominaga, H. Watanabe, T. Satoh, H. Enei, and O. Akita, *J. Biosci. Bioeng.*, 2003, **95**, 82.
16. F. J. Jin, J. Maruyama, P. R. Juvvadi, M. Arioka, and K. Kitamoto, *Biosci. Biotechnol. Biochem.*, 2004, **68**, 656.
17. T. Kubodera, N. Yamashita, and A. Nishimura, *Biosci. Biotechnol. Biochem.*, 2002, **66**, 404.
18. K. Tagami, A. Minami, R. Fujii, C. Liu, M. Tanaka, K. Gomi, T. Dairi, and H. Oikawa, *ChemBioChem*, 2014, **15**, 2076.
19. H.-G. Knaus, O. B. McManus, S. H. Lee, W. A. Schmalhofer, M. Garcia-Calvo, L. M. H. Helms, M. Sanchez, K. Giangiacomo, and J. P. Reuben, *Biochemistry*, 1994, **33**, 5819.

20. C. O. Miles, A. L. Wilkins, R. T. Gallagher, A. D. Hawkes, S. C. Munday, and N. R. Towers, [\*J. Agric. Food Chem.\*, 1992, \*\*40\*\*, 234.](#)
21. D. M. Roll, L. R. Barbieri, R. Bigelis, L. A. McDonald, D. A. Arias, L.-P. Chang, M. P. Singh, S. W. Luckman, T. J. Berrodin, and M. R. Yudt, [\*J. Nat. Prod.\*, 2009, \*\*72\*\*, 1944.](#)
22. M. Ogata, J. Ueda, M. Hoshi, J. Hashimoto, T. Nakashima, K. Anzai, M. Takagi, and K. Shinya, [\*J. Antibiot.\*, 2007, \*\*60\*\*, 645.](#)
23. 'Handbook of Secondary Fungal Metabolites, 3-Volume Set', ed. by R. J. Cole, B. B. Jarvis, and M. A. Schweikert, Elsevier, 2003.
24. 'Fungal Metabolites', Vol. 2, ed. by W. B. Turner, Academic Press Inc., 1982.
25. A. E. de Jesus, C. P. Gorst-Allman, P. S. Steyn, F. R. van Heerden, R. Vleggaar, P. L. Wessels, and W. E. Hull, *J. Chem. Soc., Perkin Trans. I*, 1983, 1863.
26. K. M. Byrne, S. K. Smith, and J. G. Ondeyka, [\*J. Am. Chem. Soc.\*, 2002, \*\*124\*\*, 7055.](#)
27. W. Acklin, F. Weibel, and D. Arigoni, *Chimia*, 1977, **31**, 63.
28. S. Fueki, T. Tokiwano, H. Toshima, and H. Oikawa, [\*Org. Lett.\*, 2004, \*\*6\*\*, 2697.](#)
29. C. Young, L. McMillan, E. Telfer, and B. Scott, [\*Mol. Microbiol.\*, 2001, \*\*39\*\*, 754.](#)
30. S. Saikia, E. J. Parker, A. Koulman, and B. Scott, [\*FEBS Lett.\*, 2006, \*\*580\*\*, 1625.](#)
31. M. J. Nicholson, A. Koulman, B. J. Monahan, B. L. Pritchard, G. A. Payne, and B. Scott, [\*Appl. Environ. Microbiol.\*, 2009, \*\*75\*\*, 7469.](#)
32. C. A. Young, M. K. Bryant, M. J. Christensen, B. A. Tapper, G. T. Bryan, and B. Scott, [\*Mol. Gen. Genomics\*, 2005, \*\*274\*\*, 13.](#)
33. T. Itoh, K. Tokunaga, Y. Matsuda, I. Fujii, I. Abe, Y. Ebizuka, and T. Kushiro, [\*Nat. Chem.\*, 2010, \*\*2\*\*, 858.](#)
34. K. Tagami, C. Liu, A. Minami, M. Noike, T. Isaka, S. Fueki, Y. Shichijo, H. Toshima, K. Gomi, T. Dairi, and H. Oikawa, [\*J. Am. Chem. Soc.\*, 2013, \*\*135\*\*, 1260.](#)
35. K. Suvarna, D. Stevenson, R. Meganathan, and M. E. S. Hudspeth, *J. Bacteriol.*, 1998, **180**, 2782.
36. K. Nozawa, M. Yuyama, S. Nakajima, K. Kawai, and S. Udagawa, [\*J. Chem. Soc., Perkin Trans. I\*, 1988, 2155.](#)
37. (a) A. Minami, H. Oguri, K. Watanabe, and H. Oikawa, [\*Curr. Opin. Chem. Biol.\*, 2013, \*\*17\*\*, 555](#); (b) A. Minami, M. Shimaya, G. Suzuki, A. Migita, S. S. Shinde, K. Sato, K. Watanabe, T. Tamura, H. Oguri, and H. Oikawa, [\*J. Am. Chem. Soc.\*, 2012, \*\*134\*\*, 7246](#); (c) K. Hotta, X. Chen, R. S. Paton, A. Minami, H. Li, K. Swaminathan, I. Mathews, K. Watanabe, H. Oikawa, K. N. Houk, and C.-Y. Kim, [\*Nature\*, 2012, \*\*483\*\*, 355.](#)
38. K. Ulrich Wendt, G. E. Schulz, E. J. Corey, and D. R. Liu, [\*Angew. Chem. Int. Ed.\*, 2000, \*\*39\*\*, 2812.](#)
39. Q. Xiong, X. Zhu, W. K. Wilson, A. Ganesan, and S. P. T. Matsuda, [\*J. Am. Chem. Soc.\*, 2003, \*\*125\*\*,](#)

[9002](#).

40. (a) J. D. Rainier and A. B. Smith III, [Tetrahedron Lett.](#), 2000, **41**, 9419; (b) J. S. Clark, J. Myatt, C. Wilson, L. Roberts, and N. Walshe, [Chem. Commun.](#), 2003, 1546.
41. S. Saikia, E. J. Parker, A. Koulman, and B. Scott, [J. Biol. Chem.](#), 2007, **282**, 16829.
42. G. I. Lepesheva, and M. R. Waterman, [Biochim. Biophys. Acta](#), 2007, **1770**, 467.
43. M. Kimura, T. Tokai, N. Takahashi-Ando, S. Ohsato, and M. Fujimura, [Biosci. Biotechnol. Biochem.](#), 2007, **71**, 2105.
44. T. Tokai, H. Koshino, N. Takahashi-Ando, S. Ohsato, M. Fujimura, and M. Kimura, [Biochem. Biophys. Res. Commun.](#), 2007, **353**, 412.
45. C. A. Citron, N. L. Brock, B. Tudzynski, and J. S. Dickschat, [Chem. Commun.](#), 2014, **50**, 5224.
46. R. T. Gallagher, J. Clardy, and B. J. Wilson, [Tetrahedron Lett.](#), 1980, **21**, 239.
47. C. Liu, A. Minami, M. Noike, H. Toshima, H. Oikawa, and T. Dairi, [Appl. Environ. Microbiol.](#), 2013, **79**, 7298.
48. T. H. Fehr and W. Acklin, [Helv. Chim. Acta](#), 1966, **49**, 1907.
49. S.-M. Li, [Nat. Prod. Rep.](#), 2010, **27**, 57.
50. T. Bonits, V. Alva, O. Saleh, A. N. Lupas, and L. Heide, [PLoS One](#), 2011, **6**, e27336.
51. M.-C. Tang, H.-C. Lin, D. Li, Y. Zou, J. Li, W. Xu, R. A. Cacho, M. E. Hillenmeyer, N. K. Garg, and Y. Tang, [J. Am. Chem. Soc.](#), 2015, **137**, 13724.
52. J. Penn and P. G. Mantle, [Phytochemistry](#), 1994, **35**, 921.
53. A. E. de Jesus, P. S. Steyn, F. R. van Heerden, R. Vleggaar, P. L. Wessels, and W. E. Hull, [J. Chem. Soc., Perkin Trans. 1](#), 1983, 1847.
54. A. E. de Jesus, P. S. Steyn, F. R. van Heerden, R. Vleggaar, P. L. Wessels, and W. E. Hull, [J. Chem. Soc., Perkin Trans. 1](#), 1983, 1857.
55. M. C. González, C. Lull, P. Moya, I. Ayala, J. Primo, and E. Primo Yúfera, [J. Agric. Food Chem.](#), 2003, **51**, 2156.
56. T. Hosoe, K. Nozawa, S. Udagawa, S. Nakajima, and K. Kawai, [Chem. Pharm. Bull.](#), 1990, **38**, 3473.
57. T. Yamaguchi, K. Nozawa, T. Hosoe, S. Nakajima, and K. Kawai, [Phytochemistry](#), 1993, **32**, 1177.
58. 2ndFind: <http://biosyn.nih.gov.jp/2ndfind/>.
59. C. Kanchanabanca, W. Tao, H. Hong, Y. Liu, F. Hahn, M. Samborsky, Z. Deng, Y. Sun, and P. F. Leadley, [Angew. Chem. Int. Ed.](#), 2013, **52**, 5785.
60. L.-F. Wei, H.-Y. He, H.-X. Pan, L. Han, R. Wang, and G.-L. Tang, [Org. Lett.](#), 2014, **16**, 1578.
61. S. B. Rivera, B. D. Swedlund, G. J. King, R. N. Bell, C. E. Hussey, Jr., D. M. Shattuck-Eidens, W. M. Wrobel, G. D. Peiser, and C. D. Poulter, [Proc. Natl. Acad. Sci. U.S.A.](#), 2001, **98**, 4373.

62. T. Ozaki, P. Zhao, T. Shinada, M. Nishiyama, and T. Kuzuyama, *J. Am. Chem. Soc.*, 2014, **136**, 4837.
63. P. Adam, D. Arigoni, A. Bacher, and W. Eisenreich, *J. Med. Chem.*, 2002, **45**, 4786.
64. N. S. Bystrov, B. K. Chernov, V. N. Dobrynin, and M. N. Kolosov, *Tetrahedron Lett.*, 1975, **16**, 2791.
65. (a) K. Valegård, A. C. T. van Scheltinga, A. Dubus, G. Ranghino, L. M. Öster, J. Hajdu, and I. Andersson, *Nat. Struct. Mol. Biol.*, 2004, **11**, 95; (b) K. Valegard, A. C. T. van Scheltinga, M. D. Lloyd, T. Hara, S. Ramaswamy, A. Perrakis, A. Thompson, H. J. Lee, J. E. Baldwin, C. J. Schofield, J. Hajdu, and I. Andersson, *Nature*, 1998, **394**, 805.
66. M. E. A. Richter, N. Traitcheva, U. Knüpfer, and C. Hertweck, *Angew. Chem. Int. Ed.*, 2008, **120**, 9004.
67. A. Bauer and M. Brönstrup, *Nat. Prod. Rep.*, 2014, **31**, 35.
68. Y. Matsuda, T. Awakawa, T. Wakimoto, and I. Abe, *J. Am. Chem. Soc.*, 2013, **135**, 10962.
69. H.-C. Lin, Y. Tsunematsu, S. Dhingra, W. Xu, M. Fukutomi, Y.-H. Chooi, D. E. Cane, A. M. Calvo, K. Watanabe, and Y. Tang, *J. Am. Chem. Soc.*, 2014, **136**, 4426.
- 



**Dr. Atsushi Minami** received his Ph.D. in 2007 from Tokyo Institute of Technology. He worked as a postdoctoral fellow with Prof. Tohru Dairi at Toyama Prefectural University in 2007. He was appointed Assistant Professor at Hokkaido University and then Associate Professor in 2015. He was awarded a Young Scientist's Research Award in Natural Product Chemistry at the 42th Natural Product Chemistry Meeting in 2007 and the Incentive Award at 54th Symposium on the Chemistry of Natural Products in 2012. His present research focused on the biosynthesis of microbial natural products, and in vitro and in vivo biochemical analysis of biosynthetic enzymes.



**Chengwei Liu** was born in Jilin, China, in 1981. He received his M.Sc. in Bioresource (2011) from Akita Prefectural University and his Ph.D. (2014) in Chemical Sciences and Engineering from Hokkaido University. In the same year, he joined the research group of professor Hideaki Oikawa for a postdoctoral position. He was appointed an Assistant Professor at Hokkaido University in 2015. His research interests include elucidation of biosynthetic pathways of natural product, and engineered biosynthesis of natural products through recombination system.





**Professor Hideaki Oikawa** received his Ph.D. degree in 1984 from Hokkaido University. He worked as a postdoctoral fellow with Prof. D. E. Cane at Brown University from 1984 and with Dr. K. Isono at RIKEN in Japan from 1985. He joined the faculty of agriculture, Hokkaido University, as an assistant professor in 1986 and was promoted to Associate Professor in 1999. He moved to the Division of Chemistry, Graduate School of Science at Hokkaido University as a Professor in 2003. From 2010 to 2015, he was a project leader of MEXT research on innovative areas ‘Biosynthetic Machinery: Deciphering and Regulating the System for Creating Structural Diversity of Bioactive Metabolites’. His present research focused on engineering of biosynthesis of natural products, reaction mechanism on C-C bond forming enzymes and genome mining of bioactive metabolites. He is a recipient of Award for Encouragement of Young Scientists from the Japan Society of Bioscience, Biotechnology, and Agrochemistry in 1993; the Chemical Society of Japan Award for Creative Work in 2004.